Journal Scans
Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer
T790M Mutation Predicts TKI Response Duration in NSCLC
K-Y Su, H-Y Chen, K-C Li, P-C Yang, et al
20120003
2012 Jan 3
J Clin Oncol
Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer
J Clin Oncol. 2012 Jan 3;[Epub Ahead of Print], K-Y Su, H-Y Chen, K-C Li, P-C Yang, et al
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the standard first-line treatment for patients with non–small-cell lung cancer (NSCLC) who have EGFR-activating mutations. However, the majority of patients eventually develop resistance to TKIs.EGFR mutation at T790M is responsible for more than 50% of acquired TKI resistance, but the mechanism of how tumors cells acquire T790M is unclear. T790M mutations may exist at low frequencies before TKI treatment (de novo resistance)...
